Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Forest Laboratories, Inc.    FRX

News SummaryMost relevantAll newsSector newsTweets 

Forest Labs 4Q Net Falls 40% As Lexapro Patent Expires; Has Upbeat Year View

share with twitter share with LinkedIn share with facebook
share via e-mail
04/17/2012 | 02:41pm CEST

Forest Laboratories Inc.'s (>> Forest Laboratories, Inc.) fiscal fourth-quarter earnings fell 40% as generic competition to its depression treatment Lexapro hurt sales, though margins improved.

The company forecast fiscal 2013 earnings of $1.20 to $1.35 a share, while analysts surveyed by Thomson Reuters expect $1.08 a share.

Like many drug makers, Forest Labs is looking to bolster its pipeline as it lost patent protection on its main money maker, Lexapro, on March 14, and its No. 2 drug, the Alzheimer's and dementia treatment Namenda, loses exclusivity in 2015. The company acquired Clinical Data Inc. last year, in hopes antidepressant Viibryd may help offset lower Lexapro sales, and earlier this month it bought the high-blood pressure drug Bystolic from Johnson & Johnson's (JNJ) Janssen Pharmaceutica NV for a one-time cash payment of $357 million, eliminating all future royalties.

Sales of Lexapro dropped 40% to $355.8 million in the most recent quarter, while Namenda sales increased about 20% to $393.1 million.

For the quarter ended March 31, Forest Labs reported a profit of $192.7 million, or 72 cents a share, down from $322.5 million, or $1.12, a year earlier. Excluding items such as acquisition-related amortization, earnings fell to 78 cents from $1.14. Revenue dropped 7.3% to $1.06 billion.

Analysts polled by Thomson Reuters had most recently forecast earnings of 70 cents on revenue of $1.02 billion.

Operating margin rose to 79.8% from 64.1% as input costs dropped 8.4%.

The company increased its selling, general and administrative costs 17% to support new products, such as Viibryd and the chronic obstructive pulmonary disease treatment Daliresp, which became available in June.

Shares closed Monday at $33.64 and were inactive premarket. The stock is up 11% so far this year.

-By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com

Stocks mentioned in the article : Forest Laboratories, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
2014 FOREST LABORATORIES : Actavis and Forest Receive U.S. FTC Clearance for Actavis&..
2014 FOREST LABORATORIES : Actavis and Forest Announce Preliminary Stockholder Merger..
2014DJAffiliated Managers Group to Join S&P 500
2014DJU.S. HOT STOCKS : Hot Stocks to Watch
2014 FOREST LABORATORIES : Announces Positive Topline Results from Three Phase III Tr..
2014DJFOREST LABORATORIES : Labs Posts Positive Results for Anxiety Disorder Drug
2014 FOREST LABORATORIES : Actavis and Forest Laboratories Announce Appointment of C...
2014 FOREST LABORATORIES : to Present Cariprazine Data at the International College o..
2014 FOREST LABORATORIES : Obtains Six Months U.S. Pediatric Exclusivity for NAMENDA®..
2014 FOREST LABORATORIES : COPD Foundation Releases Groundbreaking COPE Survey Result..
More news
Sector news : Pharmaceuticals - NEC
03/29 FDA, Mylan silence on generic Advair may be good news for GSK
03/29 British business navigates rocky path to Brexit
03/29 ConvaTec's majority investors raise $1.2 billion via stake sale
03/28DJSenator McCaskill Begins Probe of Prescription Opioid Marketing -- 2nd Update
03/28DJSHIRE : Files 8K - Other Events
More sector news : Pharmaceuticals - NEC
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON9.19%340 651
ROCHE HOLDING LTD.8.73%221 256
PFIZER INC.5.17%203 427
NOVARTIS AG-0.34%196 620
MERCK & CO., INC.7.59%173 904
More Results